

PRODUCT MONOGRAPH

Pr Piperacillin for Injection

USP

2 g, 3 g and 4 g Single-Use Vial
40 g Pharmacy Bulk Vial

Antibiotic

Fresenius Kabi Canada Ltd.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8

Date of Revision:
April 14, 2020

Submission Control Number: 233968

PRODUCT MONOGRAPH

Pr Piperacillin for Injection

2 g, 3 g and 4 g Single-Use Vial
40 g Pharmacy Bulk Vial

Antibiotic

ACTIONS AND CLINICAL PHARMACOLOGY

Piperacillin is a semi-synthetic beta-lactam antibiotic which is bactericidal and exerts its antibacterial action by inhibiting both septum and cell-wall synthesis in the bacterial cell.

Piperacillin was shown to have a particularly high affinity for PBP-3 and also a high affinity for PBP-1A, -1B and -2 of *Escherichia coli* and *pseudomonas*. These results indicate that the enzymes involved in septum (PBP-3) and cell-wall (PBP-1A, -1B) synthesis and in the maintenance of the shape (PBP-2) of the bacterium are the primary sites of action of piperacillin.

Piperacillin is eliminated primarily (60 – 80%) by glomerular filtration and tubular secretion as unchanged drug in the urine. The mean elimination half-life is 54 minutes after the administration of 2 grams and 63 minutes following 6 grams. The elimination half-life is increased two-fold in mild to moderate renal impairment and five- to six-fold in severe renal impairment.

INDICATIONS AND CLINICAL USES

Piperacillin for Injection is recommended for the treatment of systemic and local infections due to susceptible strains of gram-negative and gram-positive aerobic and anaerobic bacteria listed below. Because of its broad spectrum activity, Piperacillin for Injection is also suitable for the therapy of mixed infections, and the presumptive therapy of serious infections, when piperacillin-sensitive pathogens are suspected as the cause of disease.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin for Injection and other antibacterial drugs, Piperacillin for Injection should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

- a) **Intra-abdominal infections**, including hepato-biliary and surgical infections caused by *Escherichia coli*, *Pseudomonas aeruginosa*, *enterococci*, *Clostridium spp.*, *anaerobic cocci*, and *Bacteroides spp.*, including *B. fragilis*.

- b) **Urinary tract infections**, (complicated and uncomplicated) caused by *Escherichia coli*, *Klebsiella spp.*, *Pseudomonas aeruginosa*, *Proteus mirabilis* and *enterococci*.
- c) **Gynecological infections**, including endometritis and pelvic inflammatory disease, caused by *Bacteroides spp.*, including *B. fragilis*, *anaerobic cocci*, *Neisseria gonorrhoeae*, and *enterococci (Streptococcus faecalis)*.
- d) **Septicemia**, including bacteremia caused by *Escherichia coli*, *Klebsiella spp.*, *Serratia spp.*, *Proteus mirabilis*, *S. pneumoniae*, *enterococci*, *Pseudomonas aeruginosa*, *Bacteroides spp.*, and *anaerobic cocci*.
- e) **Lower respiratory tract infections**, caused by *Escherichia coli*, *Klebsiella spp.*, *Enterobacter spp.*, *Pseudomonas aeruginosa*, *Serratia spp.*, *Haemophilus influenzae*, *Bacteroides* species and *anaerobic cocci*. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not be achieved.
- f) **Skin and skin structure infections**, caused by *Escherichia coli*, *Klebsiella spp.*, *Serratia spp.*, *Acinetobacter spp.*, *Enterobacter spp.*, *Pseudomonas aeruginosa*, indole-positive *Proteus spp.*, *Proteus mirabilis*, *Bacteroides spp.*, including *B. fragilis*, *anaerobic cocci* and *enterococci*.
- g) **Bone and joint infections**, caused by *Pseudomonas aeruginosa*, *enterococci*, *Bacteroides spp.*, and *anaerobic cocci*.
- h) **Uncomplicated urethritis** caused by *Neisseria gonorrhoeae*.

Appropriate cultures should be made before initiating treatment. Presumptive therapy may be started while awaiting results of susceptibility tests. Treatment should be adjusted, if necessary, when results of these tests become available.

Mixed Infections

Piperacillin has also been shown to be clinically effective for the treatment of infections at various sites caused by streptococcus species, including Group A beta-hemolytic *Streptococcus* and *Streptococcus pneumoniae*. While infections caused solely by these organisms are ordinarily treated with narrower spectrum penicillins, mixed infections involving the above, and other organisms susceptible to piperacillin, may be effectively treated by the latter.

Piperacillin for Injection may be administered as single drug therapy in some situations where normally two antibiotics might be employed.

General

The efficacy of Piperacillin for Injection has been demonstrated in infections produced by organisms resistant to other penicillins, some aminoglycosides and cephalosporins.

Combined Therapy with Other Antibiotics

In vitro synergism has been shown between Piperacillin for Injection and some aminoglycosides in some bacterial strains. Piperacillin has been used clinically with aminoglycosides, especially in patients with impaired host defenses. Both drugs were used in full therapeutic doses.

Piperacillin for Injection can be used safely in combination with penicillinase-resistant penicillins, e.g., oxacillin, in mixed infections when beta-lactamase-positive *Staphylococcus aureus* is isolated along with piperacillin-susceptible organisms.

Piperacillin for Injection may be administered concomitantly with a cephalosporin, provided that an additive or synergistic antibacterial action of the two antibiotics is ascertained through *in vitro* tests. Based on *in vitro* data, cefoxitin should not be given with piperacillin when infections caused by organisms producing inducible β -lactamases are suspected or confirmed.

CONTRAINDICATIONS

A history of allergic reactions to any of the penicillins and/or cephalosporins.

Piperacillin for Injection when reconstituted with Lidocaine for intramuscular use is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

WARNINGS

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with penicillins. These reactions are more apt to occur in persons with a history of sensitivity to multiple allergens.

Cross-sensitivity of patients to penicillins and cephalosporins has been reported. Before initiating therapy with Piperacillin for Injection, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins and other allergens.

If an allergic reaction occurs, the antibiotic should be discontinued. The usual agents (antihistamines, pressor amines and corticosteroids) should be readily available.

SERIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS, AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS NECESSARY.

Antibiotic-associated pseudomembranous colitis has been reported with nearly all antibacterial agents, including piperacillin, and may range in severity from mild to life-threatening. It is important to consider this diagnosis if significant diarrhea or colitis occurs during therapy. Mild cases usually respond to drug discontinuation alone. However, in moderate to severe cases,

management with fluids and electrolytes, protein supplementation and treatment with an oral antibacterial drug effective against *Clostridium difficile* (e.g., oral vancomycin) should be considered.

Severe Cutaneous Adverse Reactions

Severe cutaneous adverse reactions (SCAR) such as acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (FEN) have been reported in association with beta-lactam treatment. When SCAR is suspected, Piperacillin for Injection should be discontinued and appropriate therapy and/or measures should be taken.

PRECAUTIONS

While Piperacillin for Injection possesses the characteristic low toxicity of the penicillin group of antibiotics, it is advisable to check periodically for organ dysfunction (including renal, hepatic and hematopoietic) during prolonged therapy.

Bleeding manifestations have occurred in some patients receiving beta-lactam antibiotics including piperacillin. These reactions have sometimes been associated with abnormalities of coagulation tests such as clotting time, platelet aggregation and prothrombin time, and are more likely to occur in patients with renal failure.

If bleeding manifestations or significant leukopenia occur, Piperacillin for Injection should be discontinued and appropriate therapy instituted.

The possibility of the emergence of resistant organisms and the development of superinfections should be kept in mind, particularly during prolonged treatment. If this occurs, appropriate measures should be taken.

As with other penicillins, patients may experience neuromuscular excitability or convulsions if higher than recommended doses of Piperacillin for Injection are given intravenously.

Since Piperacillin for Injection is excreted not only renally but also by the biliary route, it can be used at reduced dosage (see DOSAGE AND ADMINISTRATION) in patients with severely restricted kidney function and in those who have had nephrotoxic reactions to other drugs.

Piperacillin for Injection is a monosodium compound containing 1.85 milliequivalents (42.5 mg) of Na⁺ per gram based on molecular weight (see PHARMACEUTICAL INFORMATION). This should be considered when treating patients requiring restricted salt intake. Periodic electrolyte determinations should be made in patients with low potassium reserves, and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium reserves, receiving cytotoxic therapy or diuretics. Electrolyte and cardiac status should also be monitored during prolonged treatment in patients with impaired cardiac function.

Antimicrobials used in high doses for short periods to treat gonorrhea may mask or delay the symptoms of incubating syphilis. Therefore, prior to treatment, patients with gonorrhea should also be evaluated for syphilis. Specimens for dark field examination should be obtained from patients with any suspected primary lesion, and serologic tests should be performed. In all cases where concomitant syphilis is suspected, monthly serological tests should be made for a minimum of 4 months.

The use of some penicillins (ampicillin, amoxicillin) has been associated with morbilliform rashes in some cases of infectious mononucleosis. Piperacillin for Injection should therefore be used with caution in the treatment of infections caused by susceptible organisms in patients with infectious mononucleosis.

As with other semisynthetic penicillins, Piperacillin for Injection therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.

Because of chemical instability, Piperacillin for Injection should not be used for intravenous administration with solutions containing only Sodium Bicarbonate (see PHARMACEUTICAL INFORMATION: Incompatibility). Piperacillin for Injection should not be added to blood products.

Susceptibility/Resistance

Development of Drug Resistant Bacteria

Prescribing Piperacillin for Injection in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria.

Drug Interactions

The mixing of Piperacillin for Injection with an aminoglycoside *in vitro* can result in substantial inactivation of the aminoglycoside.

Concurrent administration of probenecid results in higher and more prolonged serum levels of piperacillin.

Whenever Piperacillin for Injection is administered concurrently with another antibiotic, the drugs should not be mixed in the same solution but must be administered separately.

Piperacillin, when used clinically in the early postoperative period, has been implicated in the prolongation of the neuromuscular blockage of vecuronium. In a controlled clinical study, the ureidopenicillins including piperacillin have been reported to prolong the action of vecuronium. Caution is indicated when piperacillin is used perioperatively with vecuronium and similar neuromuscular blocking agents.

Usage During Pregnancy or Lactation

Although reproduction studies in mice and rats performed at doses up to 4 times the human dose have shown no evidence of impaired fertility or harm to the fetus, safety of piperacillin use in

pregnant women has not been determined. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. It has been found to cross the placenta in rats.

Caution should be exercised when Piperacillin for Injection is administered to nursing mothers. It is excreted in low concentrations in milk.

Pediatric Use

Dosage for children under the age of 12 has not been established.

ADVERSE REACTIONS

Piperacillin is generally well tolerated. The most common adverse reactions have been local in nature, following intravenous or intramuscular injection. The following adverse reactions may occur:

Local Reactions

In adult clinical trials, thrombophlebitis was noted in 2.5% of patients. It is more likely to occur when an insufficiently diluted solution is injected into the vein.

Pain, erythema, and/or induration at the injection site occurred in 1% of patients. Less frequent reactions, including ecchymosis, deep vein thrombosis and hematomas, have also occurred.

Hypersensitivity Reactions

Rash and/or pruritus was noted in 2.3% of patients. Drug fever was 2% (Note: The incidence of rash and fever is higher in patients with cystic fibrosis). Other less frequent findings included vesicular eruptions, positive Coombs' tests. Anaphylactoid reactions have been reported rarely (see WARNINGS). Other dermatologic manifestations such as erythema multiforme, Stevens-Johnson Syndrome and Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS) have been reported rarely. DRESS has notably been reported when piperacillin was used in combination with tazobactam.

Gastrointestinal

Diarrhea and loose stools were noted in 3% of patients. Other less frequent reactions included vomiting, nausea and bloody diarrhea. Pseudomembranous colitis has been reported rarely.

Hepatic

Increases in liver enzymes (LDH, SGOT, SGPT), hyperbilirubinemia. Rarely, cholestatic hepatitis.

Renal

Elevations of creatinine or BUN and rarely interstitial nephritis.

Central Nervous System

Headache, dizziness, fatigue. Convulsions with high doses.

Hemic and Lymphatic

Reversible leukopenia, neutropenia, thrombocytopenia and/or eosinophilia, bleeding and decreases in prothrombin time have been reported. As with other beta-lactam antibiotics, reversible leukopenia (neutropenia) is more apt to occur in patients receiving prolonged therapy at high dosages or in association with drugs known to cause this reaction.

Serum Electrolytes

Individuals with liver disease or individuals receiving cytotoxic therapy or diuretics, were reported rarely to demonstrate a decrease in serum potassium concentrations with high doses of piperacillin.

Musculo-Skeletal

Rarely, prolonged muscle relaxation.

Other

Superinfection, including candidiasis, and hemorrhagic manifestations.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Other than general supportive treatment, no specific antidote is known. Excessive serum levels of piperacillin may be reduced by hemodialysis. As with other penicillins, neuromuscular excitability or convulsions have occurred following large intravenous doses. General supportive measures, including administration of phenytoin and barbiturates or other anticonvulsant drugs may be considered. Daily doses of piperacillin of at least 24 g have been administered to humans without observation of adverse effects.

For treatment of hypersensitivity reactions, see WARNINGS.

DOSAGE AND ADMINISTRATION

Dosage

Piperacillin for Injection may be administered intramuscularly or intravenously (either in a 3 to 5 minute injection or by infusion). Dosage and route of administration should be determined by the severity of the infection and condition of the patient.

The usual dosage of Piperacillin for Injection for serious infections is 3 to 4 g given every 4 to 6 hours as a 20 to 30 minute infusion. For serious infections the intravenous route should be used.

The maximum daily dose usually administered to adults is 24 g/day, although higher doses have been used.

Dosage Recommendations

Type of Infection	Usual Total Daily Dosage	Frequency of Administration
Serious infections such as septicemia, nosocomial pneumonia, intra-abdominal infections, aerobic and anaerobic gynecologic infections, and skin and soft tissue infections.	12 – 18 g intravenous (200 – 300 mg/kg)	Every 4 to 6 hours
Complicated urinary tract infections	8 – 16 g intravenous (125 – 200 mg/kg)	Every 6 to 8 hours
Uncomplicated urinary tract infections and most community-acquired pneumonia	6 – 8 g intramuscular or intravenous (100 – 125 mg/kg)	Every 6 to 12 hours
Uncomplicated gonococcal urethritis	2 g intramuscular*	Single dose

* One gram of probenecid given orally ½ hour prior to injection.

Dosage in Renal Impairment (Adults)

Degree of Renal Impairment	Creatinine		Urinary Tract Infection (Uncomplicated)	Urinary Tract Infection (Complicated)	Serious Systemic Infection
	Clearance (mL/min.)	Serum Level (mg %)			
Mild	> 40	1.5 – 3.0	N/A **	N/A **	N/A **
Moderate	20 – 40	3.1 – 5.0	N/A **	9 g/day (3 g q 8 h)	12 g/day (4 g q 8 h)
Severe	< 20	> 5	6 g/day (3 g q 12 h)	6 g/day (3 g q 12 h)	8 g/day (4 g q 12 h)
Patients on Hemodialysis ***					6 g/day (2 g q 8 h)

** N/A: No adjustment necessary

*** Hemodialysis removes 30 – 50% of the drug in 4 hours; an additional dose of 1 g of Piperacillin for Injection should be administered following each dialysis period. For patients with renal failure, hepatic insufficiency or biliary tract obstruction measurement of serum levels of Piperacillin for Injection will provide additional guidance for adjusting dosage.

Infants and Children

Dosages in infants and children under 12 years of age have not been established.

Duration of Therapy

The average duration of Piperacillin for Injection treatment is from 7 to 10 days, except in the treatment of gynecologic infections, in which it is from 3 to 10 days; the duration should be guided by the patient's clinical and bacteriological progress. Some infections such as osteomyelitis may require significantly longer periods of therapy. For most acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asymptomatic.

Antibiotic therapy for Group A beta-hemolytic streptococcal infections should be maintained for at least 10 days to reduce the risk of rheumatic fever or glomerulonephritis.

Administration

Intramuscular Injection:

Intramuscular injections should be limited to 2 g per injection site. This route of administration has been used primarily in the treatment of patients with uncomplicated gonorrhea and urinary tract infections. Injection should be given into the upper outer quadrant of the buttock (i.e., gluteus maximus).

When indicated by clinical and bacteriological findings, intramuscular administration of 6 to 8 g daily of Piperacillin for Injection, in divided doses, may be utilized for initiation of therapy. In addition, intramuscular administration of the drug may be considered for maintenance therapy after clinical and bacteriological improvement has been obtained with intravenous Piperacillin for Injection treatment.

The deltoid area should be used only if well-developed, and then only with caution to avoid radial nerve injury. Intramuscular injections should not be made into the lower or mid-third of the upper arm.

Intravenous Injection (Bolus):

Reconstituted solution should be injected slowly over a 3 to 5 minute period to help avoid vein irritation.

Intravenous Infusion:

Infusion should be carried out over a period of about 20 – 40 minutes or intermittent infusion over a 30-minute to 2-hour period. During infusion, it is desirable to discontinue the primary intravenous solution.


PHARMACEUTICAL INFORMATION

Drug Substance

Common Name: piperacillin sodium

Chemical Name: 6-[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, monosodium salt.

Structural Formula:



Molecular Formula: C₂₃H₂₆N₅NaO₇S

Molecular Weight: 539.54 g/mol

Description: Piperacillin sodium is a white to off-white hygroscopic, crystalline powder which is readily soluble in water and gives a colourless to pale-yellow solution. The pH of the aqueous solution is 5.5 to 7.5. The melting point is about 185 °C to 187 °C. It is very soluble in water, slightly soluble in ethanol, very slightly soluble in acetone, and practically insoluble in chloroform and in ether.

Composition: Vials contain piperacillin sodium equivalent to the labelled amount of piperacillin. The sodium content (Na⁺), based on the molecular weight, is 1.85 mEq/g (42.5 mg/g).

Piperacillin for Injection 2 g/vial: each vial contains piperacillin sodium equivalent to piperacillin 2 g.

Piperacillin for Injection 3 g/vial: each vial contains piperacillin sodium equivalent to piperacillin 3 g.

Piperacillin for Injection 4 g/vial: each vial contains piperacillin sodium equivalent to piperacillin 4 g.

Piperacillin for Injection 40 g/vial: each vial contains piperacillin sodium equivalent to piperacillin 40 g.

STABILITY AND STORAGE RECOMMENDATIONS

Piperacillin for Injection vials should be stored at controlled room temperature, between 15 °C and 30 °C.

Piperacillin for Injection 2 g/vial, 3 g/vial and 4 g/vial are single-use vials. Discard unused portion.

Piperacillin for Injection 40 g/vial is a Pharmacy Bulk Vial intended for multiple dispensing for **Intravenous Use Only**, employing a single puncture. Use reconstituted stock solutions within 8 hours.

RECONSTITUTION

For Intramuscular Use

Solutions for Reconstitution: Sterile Water for Injection, USP

Reconstitution Table

Vial Size	Volume to be Added	Approximate Available Volume	Approximate Available Concentration
2 g	4.0 mL	5.0 mL	0.4 g/mL
3 g	6.0 mL	7.5 mL	0.4 g/mL
4 g	8.0 mL	10.0 mL	0.4 g/mL

Shake well until dissolved.

Note: Intramuscular injections should be limited to 2 g per injection site. Injection should be given into the upper outer quadrant of the buttock (i.e., gluteus maximus).

For Intravenous Injection or Infusion

For intravenous injection or infusion, reconstitute Piperacillin for Injection with Sterile Water for Injection, USP.

Reconstitution Table

Vial Size	Volume to be Added	Approximate Available Volume	Approximate Available Concentration
2 g	10 mL	11 mL	0.18 g/mL
3 g	15 mL	17 mL	0.18 g/mL
4 g	20 mL	22 mL	0.18 g/mL

Shake well until dissolved.

The prepared solution may be further diluted to the desired volume (at least 15 mL/g for infusion) with any Intravenous Solutions listed below.

Reconstitution Table for Pharmacy Bulk Vial

Vial Size	Volume to be Added	Approximate Available Volume	Approximate Available Concentration
40 g	172 mL	200 mL	0.20 g/mL

Pharmacy Bulk Vial

THE AVAILABILITY OF THE PHARMACY BULK VIAL IS RESTRICTED TO HOSPITALS WITH A RECOGNIZED INTRAVENOUS ADMIXTURE PROGRAM.

Directions for Dispensing from Pharmacy Bulk Vial:

The Pharmacy Bulk Vial is intended for multiple dispensing for Intravenous use only, employing a single puncture. Following reconstitution, the solution should be further diluted to the desired volume in any appropriate intravenous solution of Intravenous Admixture listed below. Use reconstituted stock solutions within 8 hours and further diluted solutions within 24 hours at room temperature or 72 hours if refrigerated.

Intravenous Solutions

5% Dextrose Injection, USP (D₅W)

0.9% Sodium Chloride Injection, USP (NORMAL SALINE) [NS]

5% Dextrose and 0.9% Sodium Chloride Injection, USP (D₅NS)

Lactated Ringer's Injection, USP

Note: Because of chemical instability, Piperacillin for Injection should not be used for intravenous administration with solutions containing only sodium bicarbonate. (See INCOMPATIBILITY section.)

STABILITY OF SOLUTIONS

Stability studies have demonstrated chemical stability (pH, potency and clarity) through 24 hours at room temperature and up to 72 hours refrigerated.

Piperacillin for Injection is stable in PVC containers when reconstituted with recommended diluents and further diluted with the indicated intravenous solutions.

INCOMPATIBILITY

Piperacillin for Injection should not be added to blood products. Because of chemical instability, Piperacillin for Injection should not be used for intravenous administration with solutions containing only sodium bicarbonate.

As with all parenteral products, intravenous admixtures should be inspected for clarity of solutions, particulate matter, precipitate, discoloration, and leakage prior to administration whenever solution and container permit. Solutions showing haziness, particulate matter, precipitate, discoloration or leakage should not be used. Discard unused portion.

AVAILABILITY OF DOSAGE FORMS

Piperacillin for Injection (sterile piperacillin sodium) is available in vials containing amounts of piperacillin sodium equivalent to 2, 3 and 4 grams of piperacillin. Available in boxes of 10 vials. Also available in a pharmacy bulk vial containing piperacillin sodium equivalent to 40 g of piperacillin. Available in boxes of single-use vials.

Product Code:

8685	10 x 2 g single-use vials
8690	10 x 3 g single-use vials
8695	10 x 4 g single-use vials
8698	1 x 40 g Pharmacy Bulk Vial

Vial stoppers do not contain natural rubber latex.

MICROBIOLOGY

Piperacillin is a bactericidal, semi-synthetic penicillin with a broad spectrum of activity, encompassing both gram-negative and gram-positive anaerobic and aerobic organisms. TABLE 1, lists the minimal inhibitory concentrations (MICs) of Piperacillin for Injection for 47 119 clinical isolates tested *in vitro*.

TABLE 1
***In Vitro* Activity of Piperacillin against 47 119 Clinical Isolates**

BACTERIA	No. of Isolates Tested	% of Isolates Inhibited by (mcg/mL)					
		1**	8	16	32	64	128
<u>GRAM-NEGATIVE</u>							
<i>Acinetobacter spp.</i>	481		34	73	80	85	95
<i>Citrobacter spp.</i>	619		72	77	80	83	94
<i>Enterobacter spp.</i>	4023		73	79	84	88	91
<i>Escherichia coli</i>	8363		70	76	76	85	89
<i>Haemophilus influenzae*</i>	756	92	96	100			
<i>Klebsiella pneumoniae</i>	3538		61	70	74	86	91
<i>Klebsiella spp.</i>	2079		36	47	57	65	71
<i>Moraxella spp.</i>	22		100				
<i>Neisseria gonorrhoeae</i>	265	92	99	99			
<i>Neisseria gonorrhoeae (β-lac)</i>	44	100	100				

BACTERIA	No. of Isolates Tested	% of Isolates Inhibited by (mcg/mL)					
		1**	8	16	32	64	128
<i>Neisseria meningitidis</i>	107	97	100				
<i>Proteus (indole) spp.</i>	2747		79	83	88	92	95
<i>Proteus mirabilis</i>	3903		89	91	93	95	97
<i>Providencia spp.</i>	118		36	39	39	43	69
<i>Pseudomonas aeruginosa</i>	8604		65	80	91	95	98
<i>Pseudomonas spp.</i>	1961		61	73	81	86	94
<i>Salmonella spp.</i>	360		70	74	76	78	80
<i>Serratia marcescens</i>	1394		58	67	72	81	85
<i>Shigella spp.</i>	148		71	76	82	89	92
<i>Yersinia spp.</i>	10		70	80	90	100	
<u>ANAEROBES</u>							
<i>Bacteroides fragilis</i>	524		51	72	90	94	97
<i>Bacteroides spp.</i>	576		49	63	83	91	94
<i>Clostridium spp.</i>	90		97	99	98	100	
<i>Eubacterium spp.</i>	76		67	71	87	89	92
<i>Fusobacterium spp.</i>	54		68	70	83	96	98
<i>Peptococcus spp.</i>	197		88	88	89	94	95
<i>Peptostreptococcus spp.</i>	185		88	91	94	95	95
<i>Veillonella</i>	32		84	84	91	100	
<u>GRAM-POSITIVE</u>							
<i>Enterococci</i>	1100		90	92	93	94	95
<i>Streptococcus aureus*</i>	3162	18	69	80			
<i>Streptococcus epidermidis*</i>	635	28	83	88			
<i>Streptococcus agalactiae</i>	45		100				
<i>Streptococcus β-hemolytic</i>	32		100				
<i>Streptococcus pneumoniae</i>	314		100				
<i>Streptococcus pyogenes</i>	475		100				
<i>Streptococcus viridans</i>	49		100				
<i>Streptococcus spp.</i>	31		100				

*Includes strains of both beta-lactamase positive and negative bacteria.

** Values at 1 mcg/mL given only for those species for which this is the recommended breakpoint.

Several investigators have shown that, for about 80% of clinical isolates of both gram-negative and gram-positive bacteria that were tested, the minimum bactericidal concentration (MBC) of piperacillin was equal to or at most twice the MIC. For the majority of the remaining 20% of isolates, the MBC/MIC ratio is 4/1. Overall, the MBC/MIC ratio of piperacillin is similar to that of the aminoglycosides. Piperacillin kills isolates of *Pseudomonas* at about the same rate as cefoperazone and is 2- to 4- fold more active than moxalactam.

Table 2 lists the susceptibility of 9725 clinical isolates of gram-negative aerobic and anaerobic isolates to piperacillin. The data were obtained during 1988 from 11 geographically distinct

hospital laboratories throughout the United States. Susceptibility studies of gram-positive pathogens to piperacillin were not included in this study.

TABLE 2
***In Vitro* Activity of Piperacillin against 9725 Clinical Isolates**

Percent of Isolates

<u>ORGANISMS</u>	Percent of Isolates			
	Total #	S* ≤ 16 mcg/mL	I* 32 – 64 mcg/mL	R* ≥ 128 mcg/mL
<i>Acinetobacter spp.</i>	281	80	18	2
<i>Bacteroides fragilis</i>	293	58	25	17
<i>Citrobacter diversus</i>	122	89	7	4
<i>Citrobacter freundii</i>	227	73	13	14
<i>Enterobacter aerogenes</i>	330	64	30	5
<i>Enterobacter cloacae</i>	599	71	21	9
<i>Escherichia coli</i>	3500	79	9	12
<i>Klebsiella pneumoniae</i>	984	81	12	7
<i>Klebsiella oxytoca</i>	205	88	6	6
<i>Morganella morganii</i>	146	81	14	5
<i>Proteus mirabilis</i>	694	96	2	2
<i>Proteus vulgaris</i>	57	98	2	0
<i>Providencia rettgeri</i>	14	100	0	0
<i>Providencia atuartii</i>	36	78	17	6
<i>Pseudomonas aeruginosa</i>	1779	89	8	4
<i>Pseudomonas spp.</i>	195	37	39	24
<i>Serratia marcescens</i>	263	94	3	3
TOTAL (Average)	9725	80	13	7

* S = Susceptible, I = Intermediate, R = Resistant

In vitro, piperacillin is active against most strains of clinical isolates of the following microorganisms:

Aerobic and facultatively anaerobic organisms

Gram-negative bacteria:

- Escherichia coli*
- Proteus mirabilis*
- Proteus vulgaris**

*Morganella morganii** (formerly *Proteus morganii*)
*Providencia rettgeri** (formerly *Proteus rettgeri*)
Serratia spp. including *S. marcescens** and *S. liquefaciens**
*Klebsiella pneumoniae**
Klebsiella spp.
Enterobacter spp. including *E. aerogenes** and *E. cloacae**
Citrobacter spp. including *C. freundii** and *C. diversus**
Salmonella spp.*
Shigella spp.*
Pseudomonas aeruginosa
Pseudomonas spp. including *P. cepacia**, *P. maltophilia**, *P. fluorescens**
Acinetobacter spp. (formerly *Mima-Herellea*)
Haemophilus influenzae (non- β -lactamase-producing strains)
Neisseria gonorrhoeae
*Neisseria meningitidis**
Moraxella spp.*
Yersinia spp.* (formerly *Pasteurella*)

Gram-positive bacteria:

Group D *Streptococci* including *Enterococci* (*Streptococcus faecalis*, *S. faecium**)
 β -hemolytic *streptococci* including
Group A *Streptococcus* (*S. pyogenes**)
Group B *Streptococcus* (*S. agalactiae**)
Streptococcus pneumoniae
*Streptococcus viridans**
Staphylococcus aureus (non-penicillinase-producing)*
Staphylococcus epidermidis (non-penicillinase-producing)*

Anaerobic bacteria:

Bacteroides spp. including *B. fragilis* group (*B. fragilis*, *B. vulgatus**)
Non-*B. fragilis* group (*B. melaninogenicus**)
B. asaccharolyticus *
Clostridium spp. including *C. perfringens** and *C. difficile**
Eubacterium spp.*
Fusobacterium spp. * including *F. necleatum** and *F. necrophorum**
Peptococcus spp.*
Peptostreptococcus spp.*
Veillonella spp.*

* Piperacillin has been shown to be active *in vitro* against these organisms; however, clinical efficacy has not been established.

Piperacillin can be inactivated *in vitro* by β -lactamases produced by some strains of gram-negative and staphylococcal bacteria, however, it was found to be active against β -lactamase-producing gonococci.

In vitro testing of piperacillin combinations with gentamicin, tobramycin or amikacin shows a high incidence of synergistic action against strains of *Pseudomonas*, *Serratia*, *Klebsiella*, *Proteus* (indole-positive), *Providencia* and *Staphylococcus* species. Against other organisms, including strains of *Enterobacter* and *Acinetobacter*, partial synergy or indifference was noted. Overall, the data suggest that such combinations have clinical potential in the treatment of severe infections caused by these organisms.

Combinations of piperacillin with cephalosporin antibiotics may result in synergistic, additive, indifferent, or antagonistic effects. The effect appears to depend on the cephalosporin and the type of organism tested. Against strains of *Klebsiella*, *Escherichia coli*, *Acinetobacter*, *Proteus mirabilis*, *Salmonella*, *enterococci*, and *Staphylococcus aureus*, combinations of piperacillin with cefamandole or cefoxitin had synergistic, additive, or indifferent but no antagonistic effects. However, against *Pseudomonas*, *Enterobacter*, *Serratia*, and indole-positive *Proteus* strains, combinations of piperacillin with cefoxitin had a high frequency of antagonistic effects; combinations of piperacillin with cefamandole had additive or indifferent effects and a low frequency of antagonism.

Tests in mice reflect the *in vitro* observations. Piperacillin combinations with moxalactam, cefotaxime or cefoperazone have shown some limited *in vitro* synergy (18 – 25 % of isolates tested) against *Pseudomonas aeruginosa* and *Serratia marcescens*.

The data indicate that piperacillin-cephalosporin combinations may have clinical advantages but that susceptibility tests should be conducted.

SUSCEPTIBILITY TESTS

The use of a 100 mcg piperacillin disc with susceptibility test methods which measure zone diameter gives an accurate estimation of *in vitro* susceptibility of organisms to piperacillin. The following standard procedure has been recommended for use with discs for testing antimicrobials.* Piperacillin 100 mcg discs should be used for the determination of the susceptibility of organisms to piperacillin. With this type of procedure, a report of "susceptible" from the laboratory indicates that the infecting organism is likely to respond to therapy.

A report of "intermediate susceptibility" suggests that the organism would be susceptible if high dosage is used or if the infection is confined to tissue and fluids (e.g., bile, urine) in which high antibiotic levels are obtained. A report of "resistant" indicates that the infecting organism is not likely to respond to therapy.

With the piperacillin disc, a zone of 18 mm or greater indicates susceptibility, zone sizes of 14 mm or less indicate resistance, and zone sizes of 15 to 17 mm indicate intermediate susceptibility. (See TABLE 3.)

* NCCLS Approved Standard: M2-A3 (Formerly ASM-2) Performance Standards for Antimicrobial Disc Susceptibility Tests, Third Edition.

Haemophilus, *Neisseria* and *Staphylococcus* species which give zones of ≥ 29 mm are susceptible; resistant strains give zones of ≤ 28 mm. The above interpretive criteria is based on the use of the standardized procedure. Antibiotic susceptibility testing requires carefully prescribed procedures. Susceptibility tests are biased to a considerable degree when different methods are used.

The standardized procedure requires the use of control organisms. The 100 mcg piperacillin disc should give zone diameters between 24 and 30 mm for *Escherichia coli* ATCC No. 25922 and between 25 and 33 mm for *Pseudomonas aeruginosa* ATCC No. 27853.

Dilution methods such as those described in the International Collaboration Study⁺ and the NCCLS Approved Standard⁺⁺ have been used to determine susceptibility of the following organisms: *Enterobacteriaceae*, *Pseudomonas* species and *Acinetobacter* species are considered susceptible if the minimal inhibitory concentration of piperacillin (MIC) is no greater than 16 mcg/mL, and are considered resistant if the MIC is greater than 128 mcg/mL.

Haemophilus and *Neisseria* species are considered susceptible if the MIC of piperacillin is less than or equal to 1 mcg/mL. *Staphylococcus* species are considered susceptible if the MIC of piperacillin is less than or equal to 0.12 mcg/mL. (See TABLE 4.)

When anaerobic organisms are isolated from infection sites, it is recommended that other tests such as the modified Broth-Disk⁺⁺⁺ method be used to determine the antibiotic susceptibility of these slowly-growing organisms.

⁺ Acta Pathologica et Microbiologica Scandinavica, Section B Suppl. 217, 1971.

⁺⁺ NCCLS Approved Standards: M7-A Methods for Dilution, Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, December, 1985.

⁺⁺⁺ Wilkins, T.D., and Thiel, T. Antimicrob. Agents Chemother. 3:350-356 (March) 1973.

TABLE 3
***In Vitro* Susceptibility as Measured with 100 mcg Piperacillin Discs**

BACTERIA	PIPERACILLIN DISCS 100 mcg Zone Diameter (Millimeters)		
	Susceptible	Intermediate	Resistant
All fast-growing bacteria except those listed below	≥ 18	15 – 17	≤ 14
<i>Haemophilus spp.</i> , <i>Neisseria spp.</i> , <i>Staphylococcus spp.</i>	≥ 29		≤ 28

When minimal inhibitory concentrations (MIC) are determined by standard dilution methods⁺, the guidelines given in TABLE 4 are suggested.

⁺ Acta Pathologica et Microbiologica Scandinavica, Section B Suppl. 217, 1971.

TABLE 4
***In Vitro* Susceptibility as Measured by the Broth or Agar Dilution Method**

BACTERIA	PIPERACILLIN: MIC (mcg/mL)		
	Susceptible	Moderately Susceptible	Resistant
All bacteria, except those listed below	≤ 16	32 – 64	≥ 128
<i>Haemophilus spp.</i> , <i>Neisseria spp.</i>	≤ 1		≥ 1
<i>Staphylococcus spp.</i>	≤ 0.12		≥ 0.25

PHARMACOLOGY

Peak serum concentrations of piperacillin are attained approximately 30 minutes after intramuscular injection and immediately after intravenous injection or infusion. The serum half-life in healthy volunteers ranges from 36 minutes to 1 hour and 12 minutes. Serum levels after intravenous administration (see Table 5) and renal clearance do not show dose proportionality because of saturation of the renal secretory mechanism.

TABLE 5
Piperacillin Serum Levels in Healthy Adults (mcg/mL)

DOSE (g)	ROUTE	2 – 3 min	30 min	1 hr	2 hrs	4 hrs	6 hrs
1	intramuscular	-	21.9	14.6	9.0	2.4	0.9
2	intramuscular	-	36.4	25.8	20.2	5.8	3.1
2	intravenous Bolus	305.1	66.8	40.2	20.1	2.6	1.4
4	intravenous Bolus	412.0	116.8	92.5	38.0	8.3	3.8
6	intravenous Bolus	775.0	325.0	207.6	89.8	33.2	8.1
4	intravenous Infusion (30 min.)	244.0	141	105	53	15.3 (4.5 hrs)	3.8 (6.5 hrs.)
6	intravenous Infusion (30 min.)	353	229.0	149	73	22.2 (4.5 hrs.)	15.8

Note: Following a 30 minute infusion of 6 g every 6 hours, on the fourth day, mean peak serum concentrations were 420 mcg/mL.

Intramuscular Administration (see Table 5 above)

Piperacillin for Injection is rapidly absorbed after intramuscular injection. In healthy volunteers, the mean peak serum concentration occurs approximately 30 minutes after a single dose of 2 g and is about 36 mcg/mL.

The oral administration of 1 g probenecid before injection produces an increase in piperacillin peak serum level of about 30%. The area under the curve (AUC) is increased by approximately 60%.

The substitution of 0.5% lidocaine for Sterile Water as a diluent in an intramuscular pharmacokinetic study showed no significant difference in the area under the serum concentration curve, peak serum concentration or cumulative urine excretion of piperacillin. However, the serum half-lives were prolonged from 67 to 70 minutes at 3 g/day, 56 to 68 minutes at 4 g/day and 52 to 59 minutes at 6 g/day.

Intravenous Administration (see Table 5 above)

In healthy adult volunteers, mean serum levels immediately after a two to three minute intravenous injection of 2, 4 or 6 g were 305, 412 and 775 mcg/mL. Serum levels lack dose proportionality.

Protein Binding

Piperacillin binding to human serum proteins is 16%.

Distribution

Piperacillin is widely distributed in human tissues and body fluids, including bone, prostate, and heart and reaches high concentrations in bile (see TABLE 6). After a 4 gram bolus, maximum biliary concentrations averaged 3205 mcg/mL. It penetrates into the cerebrospinal fluid in the presence of inflamed meninges. Because Piperacillin for Injection is excreted by the biliary route (10 – 20%) as well as by the renal route, it can be used safely in appropriate dosages (see DOSAGE AND ADMINISTRATION) in patients with mild to severe renal impairment and can be used in treatment of hepato-biliary infections.

TABLE 6
Distribution of Piperacillin in
Adult Human Body Tissues and Fluids

Type of Tissue or Fluid	Tissue or Fluid Level (mcg/mL or mcg/g)	Time of Sampling (after dose)	Dose	Serum Level (mcg/mL)
Tissues				
Bone, diseased	25	at surgery	300 mg/kg infusion	385
Cardiac muscle	113.5	10 – 20 mins.	100 mg/kg intravenous bolus	500
Gallbladder	26	1 hour	2 g intravenous	166
Intestinal wall (colon)	9.3	1½ hr	2 g intravenous	12.3
Kidney, cortex	23.0 – 115.0	at surgery	4 g intravenous	NG*
Kidney, medulla	4.0 – 46.0	at surgery	4 g intravenous	NG*
Prostatic tissue	71.5	45 mins.	4 g intravenous bolus	185
Subcutaneous tissue	120	1 hr.	4 g intravenous	140
Synovial tissue	135	NG*	300 mg/kg intravenous infusion	385
Wound tissue	7	1 hr.	2 g intravenous	30
Fluids				
Bile	3247	1 a hrs	4 g intravenous	86.7
Bronchial secretions	31.4	30 – 45 mins.	4 g intravenous bolus	196.3
Cerebrospinal fluid (meningitis patients)	6.7	4¾ hrs on day 2	74.3 mg/kg intravenous infusion	7.5
Peritoneal fluid	35.5	2 hrs	50 mg/kg intravenous infusion	46.6

Type of Tissue or Fluid	Tissue or Fluid Level (mcg/mL or mcg/g)	Time of Sampling (after dose)	Dose	Serum Level (mcg/mL)
Sputum	10	NG*	4 – 16 g/day intravenous or intramuscular	> 500.0
Urine	10 000	1 hr	2 g intramuscular	36.4

* NOT GIVEN

Excretion

As with other penicillins, piperacillin is eliminated primarily by glomerular filtration and tubular secretion; it is excreted rapidly as unchanged drug in high concentrations in the urine. Approximately 60% to 80% of the administered dose is excreted in the urine in the first 24 hours. Piperacillin urine concentrations, determined by microbioassay, were as high as 1 4100 mcg/mL following a 6 g intravenous dose and 8500 mcg/mL following a 4 g intravenous dose. These urine drug concentrations remained well above 1000 mcg/mL throughout the dosing interval. The elimination half-life is increased two-fold in mild to moderate renal impairment and five-to-six-fold in severe impairment.

The mean elimination half-life of piperacillin in healthy adult volunteers is 54 minutes following administration of 2 g and 63 minutes following 6 g.

Miscellaneous

Pharmacokinetic characteristics in patients with cystic fibrosis are somewhat different than in normal subjects in that, in the former, piperacillin has a shorter half-life, a decreased volume of distribution and an increase in clearance. These differences suggest the need for either increased dosages or shortened dosage intervals in patients with cystic fibrosis.

While piperacillin reduces platelet aggregation, these effects are less than those caused by ticarcillin or carbenicillin at equivalent therapeutic dosage.

There was no significant inactivation of amikacin, gentamicin or tobramycin in serum when the aminoglycoside was administered concomitantly with carbenicillin or piperacillin to subjects with normal renal function. In the urine, lowering of the concentration of tobramycin, and gentamicin to a lesser degree, by the presence of carbenicillin or piperacillin was observed. This possible inactivation effect was greater with carbenicillin than with piperacillin. No urinary inactivation of amikacin by either of these penicillins was observed. The clinical significance of these observations is unknown.

A follow-up study was conducted in patients with end-stage renal failure stabilized on chronic intermittent hemodialysis. No inactivation of piperacillin or carbenicillin in these patients was observed when gentamicin was administered concomitantly with either of these penicillins. Carbenicillin and piperacillin, however, inactivated gentamicin in these patients. Gentamicin was inactivated 4 times faster by carbenicillin than by piperacillin.

TOXICOLOGY

Acute Toxicity

The acute median lethal dose (LD₅₀) in rats was 2 – 3 g/kg (intravenous), 7 – 10 g/kg (intraperitoneal), > 10 g/kg (subcutaneous) in 6 and 12 week old rats, and 9 g/kg (subcutaneous) in 1 week old rats; in mice, the LD₅₀ was 5 g/kg (intravenous), > 10 g/kg (subcutaneous) and 10 g/kg (intraperitoneal). Single intravenous doses of 2 and 4 g/kg were well tolerated in the dog with no changes in biochemical or hematological parameters. Signs of toxicity at 6 g/kg (intravenous) included emesis, diarrhea, salivation, and lacrimation. Slight to moderate increases in SGOT and SGPT values, white blood cell counts, and neutrophil-to-lymphocyte ratios were noted 1 day after dosing. A single 4 g/kg intravenous dose in the monkey produced similar biochemical and hematological changes and, in addition, moderate increase in lactic dehydrogenase and decreases in red blood cell counts.

Subacute and Chronic Toxicity

Rats given daily intraperitoneal doses of piperacillin (0.5 – 2 g/kg/day for 6 months and 1 – 4 g/kg/day for 1 month) showed no toxic effects except for reduced body weight gain in females at 4 g/kg/day only and in males at all dose levels.

Similar findings, plus evidence of renal damage, were seen in rats given ampicillin (2 g/kg/day for 1 month). In rats given 1, 2 or 4 g/kg twice daily intraperitoneally for 6 months, all showed an increase in lymphocytes at 4 and 6 months. At post-mortem all animals had unilateral hydronephrosis and some had urinary bladder urothelial hyperplasia, probably due to local irritation.

Dogs were given piperacillin for 1 month (up to 1 g/kg/day) intramuscular (compared with ampicillin) and intravenous (alone and with gentamicin) and for 6 months (up to 2 g/kg/day intravenous). Transient increases in blood serum enzyme values, increases in kidney and liver weights, and mild local irritation at the injection site were seen in the 1-month intramuscular study in both piperacillin- and ampicillin-treated dogs. No other toxic effects were seen in the adult dog studies and there was no synergistic toxicity when piperacillin was combined with gentamicin.

Special Toxicity Studies

Daily intravenous administration of 0.5 – 1 g/kg/day for 1 month in the rat did not cause loss of pinna reflex (as a measurement of ototoxic effect) at any frequency from 200 – 20 000 Hz.

In 4 dogs, daily administration of 2 g/kg intravenously for 1 month resulted in no drug-induced changes in liver or kidney on electron microscopic examination. The same animals showed no eye abnormalities observable by gross examination or direct ophthalmoscopy.

Reproduction and Teratology

Subcutaneous or intravenous administration of piperacillin sodium (0.5, 1 or 2 g/kg) to mice prior to mating (and in females extending into early gestation), during the period of organogenesis, or during late gestation and through the lactation period, had no adverse effect on

reproductive success or the development of offspring. Survival rates, weaning rates and body weights were higher in offspring of treated dams than controls.

In rats, with the possible exception of a slight decrease in the survival rate of pups of high-dose dams, subcutaneous administration of 0.25 – 1 g/kg of piperacillin sodium during the period of organogenesis had no adverse effects on reproductive success or the development of offspring.

Intraperitoneal doses of 0.5, 1.0, and 2.0 g/kg/day, given to rats (males for 9 weeks prior to mating and females for 2 weeks prior to mating and until the offsprings were weaned) had no adverse effects except at the 2 g/kg/day dose level where longer pre-coital time and a lower pregnancy rate were noted; no firm conclusions can be drawn. In the offspring of these animals, no adverse effects regarding early neonatal development, fertility and reproductive performance attributable to treatment of the parents with piperacillin sodium were demonstrated.

In rabbit teratology range finding studies, intravenous doses of 0.25 to 1 g/kg/day of piperacillin sodium from day 6 to 18 of gestation produced marked decreases in food intake and body weight. Maternal mortality and intrauterine deaths were high in all treatment groups; however, fetuses which did survive had no external morphologic abnormalities. Similar results were seen in dams dosed with 1 g/kg/day (single dose or 0.5 g/kg b.i.d.) from day 6 to 8 of gestation.

Mutagenicity

Piperacillin was non-mutagenic in *in vivo* cytogenetics, Ames Test, Host-Mediated (mouse) assay, Induction of Unscheduled DNA Synthesis, and Dominant Lethal test systems.

Local Irritation

An injection of 0.05 mL of 250 – 500 mg/mL piperacillin given intracutaneously in the rat produced local reaction similar to ampicillin and carbenicillin.

In the rabbit eye, a single 0.1mL instillation of 500 mg/mL piperacillin produced no changes at 24 or 72 hours. Single or multiple intramuscular injections of piperacillin 25, 35 or 40% in Sterile Water were similar to or less irritating than carbenicillin in rabbits.

Single or multiple injections of piperacillin 25 or 40% solutions in either saline (with and without lidocaine) or Sterile Water (with and without lidocaine) were generally well tolerated, though aqueous solutions were better tolerated than saline solutions.

Single injections of piperacillin 40% solution in saline or Sterile Water solution with lidocaine were better tolerated than 2.5% solutions of tetracycline HCl. In another rabbit study 0.05 mL of a 200 mg/mL solution was injected into an occluded auricular vein for 3 minutes, three times daily for three days. Piperacillin was somewhat less irritating than the carbenicillin or ampicillin controls when incidence, onset or length of thrombus were compared.

Effects on Blood

Concentrations up to 500 mg/mL piperacillin sodium did not produce hemolysis of rabbit erythrocytes *in vitro*; using human erythrocytes hemolysis was produced at concentrations higher

than 240 mg/mL. Ampicillin and carbenicillin produced hemolysis at concentrations of 200 mg/mL and higher with human erythrocytes.

Bleeding time in mice was unchanged at intravenous doses of 250 mg/kg piperacillin sodium, but increased at doses of 500 and 1000 mg/kg. Increases were seen with 1000 mg/kg of ampicillin and carbenicillin.

Neither piperacillin sodium, ampicillin nor carbenicillin affected rabbit blood prothrombin and partial thromboplastin time *in vitro* at 10^{-5} to 10^{-3} g/mL; all compounds prolonged PT and PTT at 10^{-2} g/mL.

IV doses of 0.5 or 1.0 g/kg of the same compounds did not affect PT but decreased PTT.

Concentrations of piperacillin sodium, ampicillin and carbenicillin from 10^{-5} to 10^{-3} g/mL did not affect platelet aggregation induced by adenosine diphosphate or collagen; all compounds inhibited aggregation at a concentration of 10^{-2} g/mL.

Possible Immune Responses

No skin sensitization occurred with doses of 1, 5, and 10 mg/0.5 mL of piperacillin sodium in guinea pigs. No signs of anaphylaxis were seen in guinea pigs at doses of 3 to 150 mg/kg. Protein conjugates of piperacillin sodium produced only slightly positive Arthus reactions after subcutaneous injection in rabbits. Cross reactivity (passive cutaneous anaphylaxis) of piperacillin sodium with ampicillin or penicillin G was weak, displaying 1/8 and 1/16 of the titers from the homologous antigen-antibody systems.

BIBLIOGRAPHY

1. Adam D, Reichart B and Rothenfusser B.
Diffusion of piperacillin into human heart muscle. *Current Chemotherapy and Infectious Disease, Proceedings from the 11th ICC and the 19th ICAAC*. 1980; 1:307-308.
2. Baier R, Puppel H, Zelder O and Zehner R.
The pharmacokinetics of piperacillin - data on serum, bile and urine. 20th ICAAC, New Orleans; 1980. Program and Abstracts (Abstract 754).
3. Bouza E, Buzon L, Martinez-Beltran J, Rodrigues M, Moneo I and Burgaleta C.
Complications of the treatment of bacterial infections with piperacillin. *Current Chemotherapy and Infectious Disease. Proceedings of 11th ICC and 19th ICAAC*. 1980; 1:300-303.
4. Batra VK, Morrison JA, Lasseter KC, et al.
Piperacillin kinetics. *Clinical Pharmacology and Therapeutics* 1979; 26:41-53.
5. Bodey GP, Ho DH and Elting L.
Survey of Antibiotic Susceptibility among Gram-Negative Bacilli at a Cancer Hospital. *American Journal of Medicine* 1988; 85 (suppl 1A):49-51.
6. Bruckner O, Trautman M, Martens F.
Serum pharmacokinetics of piperacillin in cirrhosis patients. *Zeitschrift fur antimikrobielle antineoplastische Chemotherapie* 1985; 3:79-83.
7. Chattopadhyay B, Hall I and Curnow SR.
Comparative *in-vitro* activity of ticarcillin, piperacillin, azlocillin and mezlocillin. *Current Medical Research and Opinion* 1983; 8(8):577-580.
8. Cuchural GJ, Tally FP, Jacobus NV, et al.
Susceptibility of the *Bacteroides fragilis* Group in the United States: Analysis by Site of Isolation. *Antimicrobial Agents and Chemotherapy* 1988; 32(5):717-722.
9. Dickinson GM, Droller DG, Greenman RL and Hoffman TA.
Piperacillin therapy for serious infections. 18th ICAAC, Atlanta, 1978. Program and Abstracts (Abstract 166).
10. Dickinson GM, Droller DG, Greenman RL, et al.
Clinical evaluation of piperacillin with observations on penetrability into cerebrospinal fluid. *Antimicrobial Agents and Chemotherapy* 1981; 20:481-486.
11. Drusano GL, Schimpff SC and Hewitt WL.
The Acylampicillins: Mezlocillin, Piperacillin, and Azlocillin. *Reviews of Infectious Diseases* 1984; 6:13-32.

12. Duprez P, Michaux JL and Wauters G.
Febrile episodes in compromised hosts: Results with piperacillin and cefotaxime as part of empiric therapy. 20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 483).
13. European Study Group on Antibiotic Resistance:
Susceptibility to Beta-Lactam Antibiotics in Septicemia Isolates from Twenty-Nine European Laboratories. *European Journal of Clinical Microbiology* 1987; 6(5):515-520.
14. Evans M, Wilson P, Leung T and Williams JO.
Pharmacokinetics of piperacillin following intravenous administration. *Journal of Antimicrobial Chemotherapy* 1978; 4:255-261.
15. Evans M, Leung T, Wilson P and Williams J.
Pharmacokinetics of intravenously administered antibiotics: A study of piperacillin, a new semi-synthetic penicillin. *Drugs and Experimental Clinical Research* 1979; 5(2-3):111-116.
16. Fass RJ and Helsel VL.
Comparative *In-Vitro* Activities of Apalcillin and Piperacillin Against Gram-Negative Bacilli. *Antimicrobial Agents and Chemotherapy* 1984; 26(5):660-664.
17. Fernandes CJ, Stevens DA and Ackerman VP. Comparative Antibacterial Activities of New Beta-Lactam Antibiotics against *Pseudomonas aeruginosa*. *Chemotherapy* 1985; 31:292-296.
18. Francke E, Appel G and Neu H.
Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis. *Antimicrobial Agents and Chemotherapy* 1979; 16(6):788-791.
19. Francke E, Prince A, Pancoast S and Neu H.
Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis and in patients with cystic fibrosis. *Current Chemotherapy and Infectious Disease. Proceedings of the 11th ICC and 19th ICAAC, 1979, 1980*; 1:308-310.
20. Fuentes del Toro S, Gomez A, Fuentes del Toro MA, Dasauld MC and Echeverria E.
Evaluation of piperacillin sodium in patients with gram-negative infections. 19th ICAAC, Boston, 1979. Program and Abstracts (Abstract 828).
21. Gentry LO, Jensek JJ and Natelson EA.
Effects of sodium piperacillin on coagulation of platelet function in normal human volunteers. 20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 760).
22. Giron JA, Meyers BR, Hirschman SZ, et al.
Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis. *Antimicrobial Agents and Chemotherapy* 1981; 19:279-283.

23. Green L, Dick JD, Goldberger SP, et al.
Prolonged elimination of piperacillin in a patient with renal and liver failure.
Drug Intelligence and Clinical Pharmacy 1985; 19:427-429.
24. Hewitt WL, Murphy W, Winston O and Young L.
Comparative efficacy and toxicity of piperacillin/amikacin versus carbenicillin/amikacin
in granulocytopenic patients.
20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 484).
25. Hoffler O, Koeppe P, Jansen R.
Piperacillin: pharmacokinetics in patients with normal and impaired renal function in:
Siegenthaler W., Bankert K (eds). Proceedings of a Symposium held at the Max-Planck-
Institute for Biochemistry, Martinsried-Munich, 24-25 April, 1980; 115-122.
26. Hoiby N, Bremmelgaard A and Schouenborg P.
In vitro Activity of Azlocillin, Carbenicillin, Mezlocillin and Piperacillin against
Pseudomonas aeruginosa. Scandinavian Journal of Infectious Diseases 1981; Suppl.
29:27-30.
27. Lida K, Hirata S, Nakamuta S, et al.
Inhibition of cell division of *Escherichia coli* by a new synthetic penicillin, piperacillin.
Antimicrobial Agents and Chemotherapy 1978; 14:257-266.
28. Korvick J, Yu VL and Hilf M.
Susceptibility of 100 Blood Isolates of *Pseudomonas. aeruginosa* to 19 Antipseudomonal
Antibiotics: Old and New. Diagnostic Microbiology and Infectious Disease 1987; 7:107-
111.
29. Kluge RM and Gainer RB.
Clinical effectiveness of piperacillin sodium in serious gram-negative and anaerobic
infections. Current Chemotherapy and Infectious Disease. Proceedings of 11th ICC and
19th ICAAC, 1980; 1:290-291.
30. Kwok FW, Welling PG, Bundtzen RW, Madsen PO and Craig WA.
Piperacillin pharmacokinetics in patients with varying renal function. 20th ICAAC, New
Orleans, 1980. Program and Abstracts (Abstract 759).
31. Lange H, Baier R, Fleischmann N, et al.
Elimination of piperacillin in renal impairment.
Current Chemotherapy and Immunotherapy, Proceedings of the 12th International
Congress of Chemotherapy, Florence, Italy, 19-24 July 1981. Washington, D.C.,
American Society for Microbiology, pp. 673-675.

32. Limson BM, Guanlao RF and Depakakibo KZ.
Piperacillin in the treatment of bacteremia and bacterial endocarditis. *Current Chemotherapy and Infectious Disease, Proceedings of 11th ICC and 19th ICAAC*, 1980; 1:297-299.
33. Linglof TO, Cars O and Nordbring F.
Piperacillin in the treatment of severe infections: Clinical evaluation and pharmacokinetics in serum, wound fluid and subcutaneous tissues. *Current Chemotherapy and Infectious Disease, Proceedings of 11th ICC and 19th ICAAC*, 1980; 1:285-287.
34. Lutz FB and Mogabgag WJ.
Therapeutic efficacy of piperacillin in serious infections in adults. 18th ICAAC, Atlanta, 1978. Program and Abstracts (Abstract 303).
35. Marier RL and Sanders CV.
Piperacillin vs carbenicillin in the therapy of severe infections. 20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 481).
36. Morrison A, Batra VK.
Pharmacokinetics of piperacillin sodium in man. *Drugs Under Experimental and Clinical Research* 1979; 5:105-110.
37. Morrison JA, Dornbush AC, Sathe SS, et al.
Pharmacokinetics of piperacillin sodium in patients with various degrees of impaired renal function. *Drugs Under Experimental and Clinical Research* 1981; 7:415-419.
38. Meyers B, Hirschman S, Strougo L and Srulevitch E.
Comparative study of piperacillin, ticarcillin and carbenicillin therapeutics. *Antimicrobial Agents and Chemotherapy* 1980; 17(4):609-611.
39. Noguchi H, Matsuhashi M and Mitsuhashi S.
Comparative studies of penicillin-binding proteins in *Pseudomonas aeruginosa* and *E. coli*. *European Journal of Biochemistry* 1979; 100:41-49.
40. Noguchi H, Matsuhashi M, Nikaido T, et al.
Affinities of beta-lactam antibiotics to bind to penicillin-binding protein in *Escherichia coli* and *Pseudomonas aeruginosa* in relation to their antibacterial potencies, in: Mitsuhashi S(ed): *Microbial Drug Resistance*, Baltimore, University Park Press, vol. 2, 1979; 361-387.
41. Patzer J, Walkiewicz R and Dzierzanowska D.
Susceptibility of *Pseudomonas aeruginosa* strains isolated from hospitalized children. *Journal of Antimicrobial Chemotherapy*. 1986; 18:45-49.

42. Philippon A.
Susceptibility of *Pseudomonas aeruginosa* to Beta-lactam Antibiotics, *chemotherapie* IV(6). 1985; 424-428.
43. Prince AS and Neu HC.
Use of piperacillin, a semi-synthetic penicillin in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis. *Journal of Pediatrics* 1980; 9(1):148-151.
44. Prince AS, Pancoast SJ and Neu HC.
Efficacy of piperacillin in the therapy of serious infections. *Current Chemotherapy and Infectious Disease, Proceedings of 11th ICC and 19th ICAAC*, 1980; 1:295-296.
45. Sander S, Bergan T and Fossberg E.
Piperacillin in the treatment of urinary tract infections. *Chemotherapy (Basel)* 1980; 26:141-144.
46. Santos JI, Wenerstrom G, Saxon BJ and Matsen JM.
Use of piperacillin as initial or supplanting therapy in serious bacterial infections. *Current Chemotherapy and Infectious Disease. Proceedings of 11th ICC and 19th ICAAC*, 1980; 1:287-289.
47. Schoutens E, Potvliege and Yourassowsky E.
Intramuscular piperacillin sodium in uncomplicated lower urinary tract infections: Evaluation of safety, clinical and bacteriological responses and blood levels. *Current Therapeutic Research* 1979; 26(6):848-855.
48. Shishido H and Matsumoto K.
Meningitis due to *Haemophilus influenzae* type E Biotype 4. *Journal of Clinical Microbiology* 1979; 10(6):926-927.
49. Silbermann M, Heiderdellman H, Kluge D, Reibetanz I and Dashner FD.
Concentration of piperacillin and cefotaxime in human muscle and fat tissue. 20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 755).
50. Simon GL, Snyderman DR, Tally FP and Gorbach SL. Clinical trial of piperacillin with acquisition of resistance by *Pseudomonas* and clinical relapse. *Antimicrobial Agents and Chemotherapy* 1980; 18(1):167-170.
51. Spicehandler JR, Bernhardt L, Simberkoff MS and Rahal JJ. Mezlocillin and piperacillin: A comparative clinical evaluation. *Current Chemotherapy and Infectious Disease, Proceedings of 11th ICC and 19th ICAAC*, 1980; 1:293-294.

52. Stobberingh EE, Philips JMH, Houben AW and van Boven CPA.
A Regional Survey of the Resistance to Beta-Lactam Antibiotics in Clinical Isolates of (Facultative) Aerobic Micro-organisms. *Drugs* 1988; 35 (Suppl. 2):41-44.
53. Thadepalli H, Rao B, White D and Bach V.
Clinical evaluation of piperacillin. *Chemotherapy* 1980; 26:377-383.
54. Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ and Verbist L.
Piperacillin: Human pharmacokinetics after intravenous and intramuscular administration. *Antimicrobial Agents and Chemotherapy* 1978; 14(6):829-837.
55. Tjandramaga TB, Verbesselt R, De Schepper PJ, Verberckomoes R and Verbist L.
Piperacillin elimination kinetics in renal insufficiency.
20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 758).
56. Tunn U and Adam D.
Diffusion and pharmacokinetics of piperacillin in prostatic tissue.
Current Chemotherapy and Infectious Disease. Proceedings of the 11th ICC and 19th ICAAC, 1980; 1:305-306.
57. Tunn U and Adam D.
Piperacillin levels in renal tissue in patients.
20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 756).
58. Umana G, Torres H and Prada G.
Piperacillin in the treatment of bacterial infections in adults.
20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 480).
59. Van Blerk PJP, Block CS, Yourassowsky E, Schoutens E, Sander S and Bergan T.
Efficacy, safety and tolerance of piperacillin sodium in patients with urinary tract infections. *Current Chemotherapy and Infectious Disease, Proceedings of 11th ICC and 19th ICAAC, 1980*; 1:291-293.
60. Viollier AF, Standiford HC, Drusanto GL, et al.
Comparative pharmacokinetics and serum bactericidal activity of mezlocillin; ticarcillin, and piperacillin, with and without gentamicin. *Journal of Antimicrobial Chemotherapy* 1985; 15:597-606.
61. Viray-Zarbo L, Del Casal M and Gooding PG.
Piperacillin sodium in the clinical treatment of beta-lactamase positive and negative *Neisseria gonorrhoeae*. 20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 482).
62. Wade J, Schimpff S, Newman K, Standiford H, Fortner C, Young V and Wiernik P.
Piperacillin, moxalactam or ticarcillin plus amikacin: Double blind comparisons of empiric antibiotic therapy for febrile granulocytopenic patients.
20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 485).

63. Wessely J and Fekete F.
The treatment of biliary infections.
20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 479).
64. Wilson C, Greenhood G, Remington JS and Vosti KL.
Neutropenia after consecutive treatment courses with nafcillin and piperacillin.
Lancet May 26, 1979; 8126:1150.
65. Winston DJ, Murphy W, Young LS and Hewitt WL.
Piperacillin therapy for serious bacterial infections. American Journal of Medicine 1980;
69:255-261.
66. Wittmann DH and Schassan HH.
Bone levels, tissue fluid and peritoneal fluid measurements following piperacillin
administration. 20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 757).
67. Yang S.
Piperacillin in patients with serious infections.
20th ICAAC, New Orleans, 1980. Program and Abstracts (Abstract 478).
68. Kuck NA and Redin GS.
In-vitro and *in-vivo* activity of piperacillin, a new broad-spectrum semi-synthetic
penicillin.
The Journal of Antibiotics, XXXI: No. 11, November, 1978.
69. Baier R and Puppel H. *In vitro* studies with piperacillin. Comparison with other beta-
lactam antibiotics against enterobacteriaceae and *P. aeruginosa*. Medizinische Klinik
1979.
70. Shah PP, Briedis DJ, Robson HG and Conterato JP.
In-vitro activity of piperacillin compared with that of carbenicillin, ticarcillin, ampicillin,
cephalothin, and cefamandole against pseudomonas aeruginosa and enterobacteriaceae.
Antimicrobial Agents and Chemotherapy March 1979; 15:No. 3, 345-350.
71. De Schepper PJ, Tjandramaga TB, Gooding PG and Joy VA.
Piperacillin - A review of pharmacokinetic and clinical aspects.
Italian Congress of Clinical Pharmacology, Taormina (Italy) 1978.
72. Kurtz TO, Winston DJ, Martin WJ, Young LS and Hewitt WIL.
Comparative *In-vitro* activity of moxalactam (LY127935), other beta-lactam antibiotics,
and aminoglycosides.
Current Microbiology 1980; Vol. 4: 239-243.
73. Kurtz TO, Winston DJ, Bruckner DA, Martin WJ.
Comparative *In-vitro* synergistic activity of new beta-lactam antimicrobial agents and
amikacin against *Pseudomonas aeruginosa* and *Serratia marcescens*.
Antimicrobial Agents and Chemotherapy 1981; 20: No.2, 239-243, August.

74. Reed MD, Bertino JS, Aronoff SC, Husak MP, Blumer JL and Speck WT. Efficacy and pharmacokinetics of piperacillin in patients with cystic fibrosis. Rainbow Babies and Children's Hospital, Cleveland, Ohio.
75. Sanders WE, Sanders CC. Inducible β -Lactamases: Clinical and Epi demiologic Implications for Use of Newer Cephalosporins. Reviews of Infectious Diseases July-August 1988 Vol. 10: No. 4, 830-849.
76. NCCLS Approved Standard M7-A: Methods for Dilution, Antimicrobial Susceptibility. Approved Standard, December 1985.
77. NCCLS Approved Standard M2-A3: Performance Standards for Antimicrobial Disk Susceptibility Tests - Third Edition; Approved Standard, December, 1984.
78. Pipracil, Sterile Piperacillin Sodium USP, Product Monograph. Lederle/Cyanamid Canada Inc., July 15, 1992.
79. Piperacillin for Injection (Piperacillin Sodium), 2 g, 3 g, and 4 g piperacillin per vial, Hospira Standard, Product Monograph. Hospira Healthcare Corporation, March 08, 2018, Control Number: 203911.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE
PATIENT MEDICATION INFORMATION

Pr Piperacillin for Injection

USP

Read this carefully before you start taking Piperacillin for Injection and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about Piperacillin for Injection.

What is Piperacillin for Injection used for?

Piperacillin for Injection is used to treat infections.

Antibacterial drugs like Piperacillin for Injection treat only bacterial infections. They do not treat viral infections such as the common cold.

How does Piperacillin for Injection work?

Piperacillin for Injection is an antibiotic. It kills bacteria that other antibiotics may not treat effectively. You should start to feel better after 48 to 72 hours of receiving Piperacillin for Injection.

What are the ingredients in Piperacillin for Injection?

Medicinal ingredient: Piperacillin Sodium

Non-medicinal ingredient: None

Piperacillin for Injection comes in the following dosage forms:

2 g, 3 g and 4 g of piperacillin per vial

Do not use Piperacillin for Injection if:

- you are allergic to Piperacillin Sodium or any of the ingredients that are in Piperacillin for Injection. See “What are the ingredients in Piperacillin for Injection”, above.
- you are sensitive to certain numbing agents that may have been used in the preparation with your injection.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Piperacillin for Injection. Talk about any health conditions or problems you may have, including if you:

- have sensitivity to other antibiotics like penicillins or cephalosporins
- are known to have a bleeding problem
- have cystic fibrosis
- suspect that you may have syphilis or mononucleosis (mono)
- have kidney disease
- have liver disease

Other warnings you should know about:

- Piperacillin for Injection may cause seizures, shaking or convulsions.
- Piperacillin for Injection contains sodium and patients on restricted salt intake may need blood test monitoring.
- Tell your healthcare professional if you are a nursing mother. Piperacillin for Injection is excreted in human milk.

- Tell your healthcare professional if you are pregnant or plan to become pregnant. It is not known if Piperacillin for Injection will harm your unborn baby.
- Inflammation of the intestines (gut) has also been reported from using all antibiotics including Piperacillin for Injection.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with Piperacillin for Injection:

- Other antibiotics and aminoglycosides (drugs used to treat infections such as penicillin, ampicillin, amoxicillin, probenecid and gentamicin)
- Drugs that block the activity of the muscles (muscle relaxants such as vecuronium)

How to take Piperacillin for Injection:

- Although you may feel better early in treatment, Piperacillin for Injection should be used exactly as directed.
- Misuse or overuse of Piperacillin for Injection could lead to the growth of bacteria that will not be killed by Piperacillin for Injection (resistance). This means that Piperacillin for Injection may not work for you in the future.
- Do not share your medicine.

Adult Dose:

The maximum daily dose is 24 g/day.

Injection in the muscle: maximum of 2 g per injection site

Injection in the vein: slowly over a 3 to 5 minute period

Injection in the vein: 20 to 40 minutes (intermittent infusion: 30 minutes to 2 hour)

Dosages in infants and children under 12 years of age have not been established.

Overdose:

If you think you have taken too much Piperacillin for Injection, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

What are possible side effects from using Piperacillin for Injection?

These are not all the possible side effects you may feel when taking Piperacillin for Injection. If you experience any side effects not listed here, contact your healthcare professional.

Side effects may include:

- Redness, swelling or bruising at the injection site
- Blood clot in vein
- Fever
- Allergic reaction
- Rash, redness or itching over body or other skin conditions or skin discoloration
- Diarrhea
- Headache
- Dizziness

- Fatigue
- Convulsions (high doses)

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<p>Severe Cutaneous Adverse Reactions (SCAR) (severe skin reactions that may also affect other organs):</p> <ul style="list-style-type: none"> • Skin peeling, scaling, or blistering (with or without pus) which may also affect your eyes, mouth, nose or genitals, itching, severe rash, bumps under the skin, skin pain, skin color changes (redness, yellowing, purplish) • Swelling and redness of eyes or face • Flu-like feeling, fever, chills, body aches, swollen glands, cough • Shortness of breath, chest pain or discomfort 			√

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Piperacillin for Injection vials should be stored at controlled room temperature, between 15 °C and 30 °C. Keep out of reach and sight of children.

If you want more information about Piperacillin for Injection:

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>) or by contacting the sponsor, Fresenius Kabi Canada Ltd., at 1-877-821-7724.

This leaflet was prepared by:

Fresenius Kabi Canada Ltd.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8

Last Revised: April 14, 2020